Effect of combined consumption of Lactobacillus brevis KB290 and β-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial

References

• Bjelakovic G, Nikolova D, Gluud C. 2013. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 8:e74558.
   PubMed Web of Science ®Google Scholar
• Cain KC, Headstrom P, Jarrett ME, Motzer SA, Park H, Burr RL, Surawicz CM, Heitkemper MM. 2006. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol. 101:124–132.
   PubMed Web of Science ®Google Scholar
• Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. 2017. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis. World J Gastroenterol. 23:336–344.
   PubMed Web of Science ®Google Scholar
• Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL. 2014. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One. 9:e93144.
   PubMed Web of Science ®Google Scholar
• Druesne-Pecollo N, Latino-Martel P, Norat T, Barrandon E, Bertrais S, Galan P, Hercberg S. 2010. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer. 127:172–184.
   PubMed Web of Science ®Google Scholar
• Ehlin AGC, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. 2003. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut. 52:1117–1121.
   PubMed Web of Science ®Google Scholar
• Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM. 2015. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 114:1638–1646.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Nomura S. 2008. A prospective study of the psychobehavioral factors responsible for a change from non-patient irritable bowel syndrome to IBS patient status. Biopsychosoc Med. 2:16.
   PubMedGoogle Scholar
• Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. 2014. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 12:953–959.e4.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K. 2016. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 150:258–366e8.
   Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K. 2016. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 51:1–9.
   Google Scholar
• Fukuhara S, Suzukamo Y. 2004. Manual of the SF-8 Japanese version. [place unknown].
   Google Scholar
• Gao J. 2013. Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Exp Ther Med. 6:93–96.
   PubMed Web of Science ®Google Scholar
• González-Domínguez É, Samaniego R, Flores-Sevilla JL, Campos-Campos SF, Gómez-Campos G, Salas A, Campos-Peña V, Corbí ÁL, Sánchez-Mateos P, Sánchez-Torres C. 2015. CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo. J Leukoc Biol. 98:453–466.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. 2000. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 119:654–660.
   PubMed Web of Science ®Google Scholar
• Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. 2009. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr. 102:1654–1662.
   PubMed Web of Science ®Google Scholar
• Gwee K-A, Bak Y-T, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, Chua ASB, Lu CL, Goh KL, Kositchaiwat C, et al. 2010. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol. 25:1189–1205.
   PubMed Web of Science ®Google Scholar
• Hart AL, Stagg AJ, Kamm MA. 2003. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 36:111–119.
   PubMed Web of Science ®Google Scholar
• Ishihara S, Tada Y, Fukuba N, Oka A, Kusunoki R, Mishima Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kinoshita Y. 2013. Pathogenesis of irritable bowel syndrome – review regarding associated infection and immune activation. Digestion. 87:204–211.
   PubMed Web of Science ®Google Scholar
• Krogsgaard LR, Engsbro AL, Bytzer P. 2013. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults ≤50 years of age. Scand J Gastroenterol. 48:523–529.
   PubMed Web of Science ®Google Scholar
• Layer P, Stanghellini V. 2014. Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 39:371–384.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu B, Chen S, Wang M, Liu Y, Zhang Y, Yao S. 2014. Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients. J Zhejiang Univ Sci B. 15:907–914.
   PubMed Web of Science ®Google Scholar
• Macsharry J, O’mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM. 2008. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 43:1467–1476.
   PubMed Web of Science ®Google Scholar
• Min YW, Rhee P-L. 2015. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol. 8:136–142.
   PubMed Web of Science ®Google Scholar
• Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. 2012. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 6:16.
   PubMedGoogle Scholar
• Di Nardo G, Barbara G, Cucchiara S, Cremon C, Shulman RJ, Isoldi S, Zecchi L, Drago L, Oliva S, Saulle R, et al. 2014. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol Motil. 26:196–204.
   PubMed Web of Science ®Google Scholar
• Nobuta Y, Inoue T, Suzuki S, Arakawa C, Yakabe T, Ogawa M, Yajima N. 2009. The efficacy and the safety of Lactobacillus brevis KB290 as a human probiotics. Int J Probiotics Prebiotics. 4:263–270.
   Google Scholar
• O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM, et al. 2005. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128:541–551.
   PubMed Web of Science ®Google Scholar
• Paré P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR. 2006. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 28:1726–1735. discussion 1710–11.
   PubMed Web of Science ®Google Scholar
• Qin H-Y, Wu JCY, Tong X-D, Sung JJY, Xu H-X, Bian Z-X. 2011. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 46:164–174.
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, et al. 2012. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 107:1714–24.
   Web of Science ®Google Scholar
• Reilly MC, Bracco A, Ricci J-F, Santoro J, Stevens T. 2004. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 20:459–467.
   PubMed Web of Science ®Google Scholar
• Rivollier A, He J, Kole A, Valatas V, Kelsall BL. 2012. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med. 209:139–155.
   PubMed Web of Science ®Google Scholar
• Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. 2010. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 31:218–227.
   PubMed Web of Science ®Google Scholar
• Singh P, Staller K, Barshop K, Dai E, Newman J, Yoon S, Castel S, Kuo B. 2015. Patients with irritable bowel syndrome – diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 21:8103–8109.
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. 2000. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811.
   PubMed Web of Science ®Google Scholar
• Torii A. 2008. Survey on stool abnormality and irritable bowel syndrome patients in Japan: a questionnaire survey for general population. Shindan to Chiryo 96:221–230.
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration C for DE and R (CDER). 2012. Guidance for Industry, Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment.
   Google Scholar
• Vicario M, González-Castro AM, Martínez C, Lobo B, Pigrau M, Guilarte M, de Torres I, Mosquera JL, Fortea M, Sevillano-Aguilera C, et al. 2014. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut. 64:1379–1388.
   PubMed Web of Science ®Google Scholar